Hematopoietic growth factors in prophylaxis and treatment of infectious complications in neonates;Häimatopoetische wachstumsfaktoren in prophylaxe und therapie infektiöser komplikationen bei früh- und neugeborenen

Zeitschrift fur Geburtshilfe und Neonatologie

Volumn 205, Issue 5, 2001, Pages 167-173

  Lehrnbecher, T ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

G CSF (granulocyte colony stimulating factor); GM CSF (granulocyte macrophage colony stimulating factor); Infection; Neonate

Indexed keywords

ANTIBIOTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR;

DRUG COST; HUMAN; INFECTION RISK; INFECTIOUS COMPLICATION; NEUTROPENIA; NEWBORN; NEWBORN MORBIDITY; NEWBORN MORTALITY; NEWBORN SEPSIS; PREECLAMPSIA; PROGNOSIS; PROPHYLAXIS; REVIEW; SURVIVAL; VERY LOW BIRTH WEIGHT; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG EFFECT; IMMUNOLOGY; LEUKOCYTE COUNT; MORTALITY; NEUTROPHIL; PREMATURITY; TREATMENT OUTCOME;

BACTERIAL INFECTIONS; CLINICAL TRIALS; ENGLISH ABSTRACT; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMAN; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; INFANT, VERY LOW BIRTH WEIGHT; LEUKOCYTE COUNT; NEUTROPHILS; TREATMENT OUTCOME;

EID: 18044404276     PISSN: 09482393     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18502     Document Type: Review

References (59)

1. A ten-year review of neonatal sepsis and comparison with the previous fifty-year experience
2. Hematologic scoring system in early diagnosis of sepsis in neutropenic newborns
3. Exhaustion of mature marrow neutrophils in neonates with sepsis
4. Host defenses in the neonate: Prospects for enhancement
5. Neutrophil function in newborn infants
6. The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors
7. Binding of the differentiation-inducer, granulocyte-colony-stimulating factor, to responsive but not unresponsive leukemic cell lines
8. Binding of 1251-labeled granulocyte colony-stimulating factor to normal murine hemopoietic cells
9. High-affinity binding of granulocyte-macrophage colony-stimulating factor to normal and leukemic human myeloid cells
10. Activities of four purified growth factors on highly enriched human hematopoietic progenitor cells
11. Molecular physiology of granulocyte-macrophage colony-stimulating factor
12. Filgrastim (r-metHuG-CSF): The first 10 years
13. Granulocyte/macrophage colony-stimulating factor stimulates monocyte and tissue macrophage proliferation and enhances their responsiveness to macrophage colony-stimulating factor
14. Role of granulocyte/macrophage colony-stimulating factor in the regulation of murine alveolar macrophage proliferation and differentiation
15. Effects of recombinant human granulocyte and granulocyte-macrophage colony-stimulating factors on neutrophil function following autologous bone marrow transplantation
16. Effect of exogenous recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor on neutrophil function following allogeneic bone marrow transplantation
17. Recombinant human granulocyte-macrophage colony-stimulating factor primes neonatal granulocytes for enhanced oxidative metabolism and chemotaxis
18. Effects of in vitro and in vivo cytokine treatment, leukapheresis and irradiation on the function of human neutrophils
19. Neutrophil oxidative burst in response to blastoconidia and pseudohyphae of candida albicans: Augmentation by granulocyte colony-stimulating factor and interferon-gamma
20. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils
21. Synergy of simultaneous administration of ofloxacin and granulocyte colony-stimulating factor in killing Escherichia coli by human neutrophils
22. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products
23. Cell acidification in apoptosis: Granulocyte colony-stimulating factor delays programmed cell death in neutrophils by up-regulating the vacuolar H(+)-ATPase
24. Involvement of reactive oxygen intermediates in spontaneous and CD95 (Fas/APO-1)-mediated apoptosis of neutrophils
25. Cellular processing of murine colony-stimulating factor (Multi-CSF, GM-CSE G-CSF) receptors by normal hemopoietic cells and cell lines
26. High levels of granulocyte and granulocyte-macrophage colony-stimulating factors in cord blood of normal full-term neonates
27. Granulocyte and granulocyte-macrophage colony-stimulating factors in cord and maternal serum at delivery
28. Serum concentrations of granulocyte colony-stimulating factor in healthy term and preterm neonates and in those with various diseases including bacterial infections
29. Production of granulocyte colony-stimulating factor in vitro by monocytes from preterm and term neonates
30. Decreased G-CSF and IL-3 production and gene expression from mononuclear cells of newborn infants
31. Decreased stimulated GM-CSF production and GM-CSF gene expression but normal numbers of GM-CSF receptors in human term newborns compared with adults
32. A longitudinal study of granulocyte colony-stimulating factor levels and neutrophil counts in newborn infants
33. Circulating steel factor (SLF) and G-CSF levels in preterm and term newborn and adult peripheral blood
34. Haemopoietic colony stimulating factors for preterm neonates
35. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants
36. Seven-day administration of recombinant human granulocyte colony-stimulating factor to newborn rats: Modulation of neonatal neutrophilia, myelopoiesis, and group B Streptococcus sepsis
37. Prophylactic or simultaneous administration of recombinant human granulocyte colony stimulating factor in the treatment of group B streptococcal sepsis in neonatal rats
38. The ability of recombinant murine granulocyte-macrophage colony-stimulating factor to protect neonatal rats from septic death due to Staphylococcus aureus
39. Results of a phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in very low birthweight neonates: Significant induction of circulatory neutrophils, monocytes, platelets, and bone marrow neutrophils
40. A randomized, controlled trial of prophylactic granulocyte-macrophage colony-stimulating factor in human newborns less than 32 weeks gestation
41. A randomized, double-blind, placebo-controlled trial of prophylactic recombinant human granulocyte-macrophage colony-stimulating factor to reduce nosocomial infections in very low birth weight neonates
42. Incidence, neutrophil kinetics, and natural history of neonatal neutropenia associated with maternal hypertension
43. The neonatal blood count in health and disease. I. Reference values for neutrophilic cells
44. Increased incidence of sepsis at birth in neutropenic infants of mothers with preeclampsia
45. Increased nosocomial infection in neutropenic low birth weight (2000 grams or less) infants of hypertensive mothers
46. Effect of granulocyte colony-stimulating factor on preeclampsia-associated neonatal neutropenia
47. Administration of granulocyte colony-stimulating factor to neutropenic low birth weight infants of mothers with preeclampsia
48. Preliminary report: rhG-CSF may reduce the incidence of neonatal sepsis in prolonged preeclampsia-associated neutropenia
49. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: Significant induction of peripheral and bone marrow neutrophilia
50. A two-year follow-up of neonates with presumed sepsis treated with recombinant human granulocyte colony-stimulating factor during the first week of life
51. The in vivo effect of recombinant human granulocyte-colony stimulating factor in neutropenic neonates with sepsis
52. Human granulocyte colony-stimulating factor may improve outcome attributable to neonatal sepsis complicated by neutropenia
53. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia
54. A randomized, double-blind, placebo-controlled trial of granulocyte colony stimulating factor administration to treat neonatal neutropenia
55. A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis
56. Administration of recombinant human granulocyte-colony stimulating factor to septic neonates induces neutrophilia and enhances the neutrophil respiratory burst and beta2 integrin expression. Results of a randomized controlled trial
57. A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis
58. Granulocyte colony-stimulating factor serum and urine concentrations in neutropenic neonates before and after intravenous administration of recombinant granulocyte colony-stimulating factor
59. Granulocyte colony-stimulating factor receptor expression on neutrophils of term and preterm neonates with and without signs of infection